{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:17:07Z","timestamp":1793733427032,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010037","name":"Chongqing Youth Science and Technology Talent Training Project","doi-asserted-by":"publisher","award":["414Z393"],"award-info":[{"award-number":["414Z393"]}],"id":[{"id":"10.13039\/501100010037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012433","name":"Key Project of Technological Innovation Application Development Plan of Chongqing City","doi-asserted-by":"publisher","award":["CSTB2022TIAD-KPX0168"],"award-info":[{"award-number":["CSTB2022TIAD-KPX0168"]}],"id":[{"id":"10.13039\/501100012433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eclinm.2024.102585","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T15:42:24Z","timestamp":1712850144000},"page":"102585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II\/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial"],"prefix":"10.1016","volume":"71","author":[{"given":"Yan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-4957","authenticated-orcid":false,"given":"Xiaowei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102585_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.annonc.2021.11.016","article-title":"Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate","volume":"33","author":"Poggio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib2","article-title":"Neoadjuvant chemotherapy in early triple-negative breast cancer: a pairwise and network meta-analysis of pathological complete response","volume":"58","author":"Weng","year":"2021","journal-title":"Inq J Health Care Organ Provis Financ"},{"key":"10.1016\/j.eclinm.2024.102585_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770663","article-title":"Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: a narrative review","volume":"12","author":"Tian","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2024.102585_bib5","article-title":"A\u00a0prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer","volume":"14","author":"Yan","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","article-title":"Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"22","author":"Lv","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-018-03210-2","article-title":"A\u00a0randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer","volume":"9","author":"Wu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2024.102585_bib8","article-title":"Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial","volume":"14","author":"Yan","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib9","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","article-title":"Neoadjuvant bevacizumab and anthracycline\u2013taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)","volume":"24","author":"Gerber","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"Von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/annonc\/mds658","article-title":"Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: first global approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.eclinm.2024.102585_bib14","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","article-title":"Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2024.102585_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101563","article-title":"A\u00a0randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer","volume":"8","author":"Liu","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2024.102585_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.20892\/j.issn.2095-3941.2020.0463","article-title":"Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer","volume":"18","author":"Hu","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.eclinm.2024.102585_bib17","article-title":"A\u00a0phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.eclinm.2024.102585_bib18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non\u2013small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib19","doi-asserted-by":"crossref","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djx258","article-title":"Comparison of neoadjuvant nab-Paclitaxel+Carboplatin vs nab-Paclitaxel+Gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results","volume":"110","author":"Gluz","year":"2018","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2024.102585_bib22","first-page":"966","article-title":"[Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients]","volume":"42","author":"Ou","year":"2020","journal-title":"Zhonghua Zhongliu Zazhi"},{"key":"10.1016\/j.eclinm.2024.102585_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ijc.34717","article-title":"Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: a prospective cohort study with propensity-matched analysis","volume":"154","author":"Liu","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2024.102585_bib24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A\u00a0randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102585_bib26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102585_bib27","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial","author":"Sharma","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eclinm.2024.102585_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.eclinm.2024.102585_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","article-title":"Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.eclinm.2024.102585_bib32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","article-title":"Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial","volume":"25","author":"Fan","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102585_bib33","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2024.102585_bib34","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102585_bib35","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1586\/14737140.8.10.1689","article-title":"MYC in breast tumor progression","volume":"8","author":"Chen","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.eclinm.2024.102585_bib36","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.2017.77.2285","article-title":"BRCA1\/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study","volume":"36","author":"Fasching","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:03:08Z","timestamp":1778904188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024001640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"alternative-id":["S2589537024001640"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102585","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II\/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102585"}}